Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Streptococcal glucosyltransferase refers to a family of enzymes (primarily GtfB, GtfC, and GtfD) produced by *Streptococcus mutans* and related oral streptococci[5][6][7]. These enzymes catalyze the transfer of glucose residues from sucrose to form extracellular glucans, which are key structural components of dental biofilms and are essential for bacterial colonization and virulence in dental caries[5][7]. Gtfs belong to glycoside hydrolase family 70 and share a conserved catalytic domain (for sucrose binding and cleavage) with a variable C-terminal region for glucan binding[7]. They are well-recognized therapeutic targets for caries prevention and control strategies focused on disrupting biofilm formation. Inhibitors of Gtfs are being explored as anticaries agents, but clinical translation is complicated by selectivity and safety considerations[5][6][7].
Drugs/inhibitors block enzymatic activity, suppressing synthesis of water-soluble and water-insoluble glucans, thus reducing biofilm formation[5][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Streptococcal glucosyltransferase (Gtf (general); GtfB, GtfC, GtfD (specific enzymes)).